Abstract:Purpose To evaluate the performance of an artificial intelligence (AI) model in detecting overall and clinically significant prostate cancer (csPCa)-positive lesions on paired external and in-house biparametric MRI (bpMRI) scans and assess performance differences between each dataset. Materials and Methods This single-center retrospective study included patients who underwent prostate MRI at an external institution and were rescanned at the authors' institution between May 2015 and May 2022. A genitourinary radiologist performed prospective readouts on in-house MRI scans following the Prostate Imaging Reporting and Data System (PI-RADS) version 2.0 or 2.1 and retrospective image quality assessments for all scans. A subgroup of patients underwent an MRI/US fusion-guided biopsy. A bpMRI-based lesion detection AI model previously developed using a completely separate dataset was tested on both MRI datasets. Detection rates were compared between external and in-house datasets with use of the paired comparison permutation tests. Factors associated with AI detection performance were assessed using multivariable generalized mixed-effects models, incorporating features selected through forward stepwise regression based on the Akaike information criterion. Results The study included 201 male patients (median age, 66 years [IQR, 62-70 years]; prostate-specific antigen density, 0.14 ng/mL2 [IQR, 0.10-0.22 ng/mL2]) with a median interval between external and in-house MRI scans of 182 days (IQR, 97-383 days). For intraprostatic lesions, AI detected 39.7% (149 of 375) on external and 56.0% (210 of 375) on in-house MRI scans (P < .001). For csPCa-positive lesions, AI detected 61% (54 of 89) on external and 79% (70 of 89) on in-house MRI scans (P < .001). On external MRI scans, better overall lesion detection was associated with a higher PI-RADS score (odds ratio [OR] = 1.57; P = .005), larger lesion diameter (OR = 3.96; P < .001), better diffusion-weighted MRI quality (OR = 1.53; P = .02), and fewer lesions at MRI (OR = 0.78; P = .045). Better csPCa detection was associated with a shorter MRI interval between external and in-house scans (OR = 0.58; P = .03) and larger lesion size (OR = 10.19; P < .001). Conclusion The AI model exhibited modest performance in identifying both overall and csPCa-positive lesions on external bpMRI scans. Keywords: MR Imaging, Urinary, Prostate Supplemental material is available for this article. © RSNA, 2024.

Deep learning AI and Restriction Spectrum Imaging for patient-level detection of clinically significant prostate cancer on MRI

Fully Automated Deep Learning Model to Detect Clinically Significant Prostate Cancer at MRI

Deep learning model for the detection of prostate cancer and classification of clinically significant disease using multiparametric MRI in comparison to PI-RADs score

Restriction Spectrum Imaging as a quantitative biomarker for prostate cancer with reliable positive predictive value

Deep-Learning Models for Detection and Localization of Visible Clinically Significant Prostate Cancer on Multi-Parametric MRI

Autonomous Detection and Classification of PI-RADS Lesions in an MRI Screening Population Incorporating Multicenter-Labeled Deep Learning and Biparametric Imaging: Proof of Concept

A Deep Learning Approach for Predicting Clinically Significant Prostate Cancer: A Retrospective, Multicentre Study

Predicting Clinically Significant Prostate Cancer with a Deep Learning Approach: a Multicentre Retrospective Study

Deep Radiomics Detection of Clinically Significant Prostate Cancer on Multicenter MRI: Initial Comparison to PI-RADS Assessment

Deep‐Learning‐Based Artificial Intelligence for PI‐RADS Classification to Assist Multiparametric Prostate MRI Interpretation: A Development Study

Multimodal AI Combining Clinical and Imaging Inputs Improves Prostate Cancer Detection

A Validation Study of the Deep-Learning-Based Prostate Imaging Reporting and Data System Scoring Algorithm

Robustness of a Restriction Spectrum Imaging (RSI) quantitative MRI biomarker for prostate cancer: assessing for systematic bias due to age, race, ethnicity, prostate volume, medication use, or imaging acquisition parameters

External Validation of a Previously Developed Deep Learning-based Prostate Lesion Detection Algorithm on Paired External and In-House Biparametric MRI Scans

Fully automated detection and localization of clinically significant prostate cancer on MR images using a cascaded convolutional neural network

Restriction spectrum imaging: An evolving imaging biomarker in prostate MRI

PI-RADSAI: Introducing a New Human-in-the-loop AI Model for Prostate Cancer Diagnosis Based on MRI

A pilot study of AI-assisted reading of prostate MRI in Organized Prostate Cancer Testing

Automated Diagnosis of Prostate Cancer Using mpMRI Images: A Deep Learning Approach for Clinical Decision Support

Deep Learning in Prostate Cancer Diagnosis Using Multiparametric Magnetic Resonance Imaging With Whole-Mount Histopathology Referenced Delineations

Deep Learning Enhances Detection of Extracapsular Extension in Prostate Cancer from mpMRI of 1001 Patients